Physician profile
Thomas G Chaisson
NPI 1902895279
$2,941.81
in general payments reported to CMS, 2019-2025
41 companies · $361 in 2025
The $361 reported for 2025 was more than what 79% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $183 · 2021: $563 · 2022: $455 · 2023: $479 · 2024: $593 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $452.38 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Novo Nordisk INC | $272.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $213.27 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $192.19 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $146.35 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $125.06 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $121.79 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.90 | 2019-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $88.01 | 2019-2025 | Farxiga |
| Abbott Laboratories | $82.19 | 2021-2025 | Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $76.60 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.80 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $69.44 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ironshore Pharmaceuticals INC. | $65.10 | 2024 | |
| Corium, LLC | $63.14 | 2021-2023 | Azstarys |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Chaisson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.